RESUMO
Complexes of the type trans-[Re(PR3)2(Schiff base)]+ (R = ethyl and/or phenyl) 2-7 were prepared by the reaction of (nBu4N)[ReOCl4] with H2sal2en or H2sal2ibn followed by addition of a tertiary phosphine. The trans-[Re(PR3)2(sal2en)]+ complexes 2-4 were stable in solution, whereas the trans-[Re(PR3)2(sal2ibn)]+ complexes 6-7 were observed to convert to their corresponding cis-[ReO(PR3)(sal2ibn)]+ products through a process involving ligand dissociation, metal oxidation, and Schiff base ligand rearrangement. The conversion of the trans-[Re(PR3)2(sal2ibn)]+ complexes is likely driven by steric interactions between the bulky backbone gem-dimethyl groups of the sal2ibn ligand and the phosphine ligands. These complexes were isolated and characterized by 1H and 13C NMR, FT-IR spectroscopy, cyclic voltammetry, and single crystal X-ray diffraction. The results reported herein provide insight into the factors that drive trans-[Re(PR3)2(Schiff base)]+ complex formation. This will aid in the development of novel 186/188Re therapeutic agents and the design of novel bifunctional N2O2 Schiff base ligands.
RESUMO
Until recently, liver transplantation was contraindicated in Jehovah's Witness patients because of recipient-imposed restrictions on use of blood products. However, recent improvements in surgical and anaesthetic techniques and new procoagulant agents challenge this practice. We describe two Jehovah's Witness patients who had successful liver transplantation without blood transfusion. To our knowledge, these are the first such cases in Australasia. The techniques used to minimise blood loss and transfusion requirements could potentially benefit all patients undergoing major surgery.
